while this invention can be embodied in many different forms , there are shown in the drawings and described in detail , preferred embodiments of the invention . the present disclosure is an exemplification of the principles of the invention and is not intended to limit the invention to the embodiments illustrated . the present invention is a medical device and system which allow for the painless direct administration of medication into a patient . after the medical device has been surgically implanted , medication can be continuously or intermittently administered to the patient at a selected region without further pain or discomfort . in addition , the present invention allows for the easy and safe replacement of a part which may become worn through extensive use . the advantages provided by the present device are many . for instance , it is now generally accepted that insulin administered via the peritoneal fluid permits better glucose control than insulin that is administered subcutaneously . this device is particularly well suited as a peritoneal access device for the delivery of insulin as well as other medication . moreover , the device of this invention is also well suited for subcutaneous delivery of medication and delivery of medication to a particular body region as will be discussed in more detail below . a medical device 10 embodying the present invention is shown in fig1 . the device 10 is implanted transcutaneously through the epidermis and dermis 12 , the subcutaneous fatty tissue 14 and into the abdominal muscle 16 . referring to fig1 - 3 , the medical device 10 of the present invention includes an implant 20 , an insert 22 which is sealingly and releasably mounted on the implant and seal means 24 carried by the implant 20 . the seal means 24 coacts with the insert 22 to seal a cavity defined by the interior of the implant 20 from the ambient surroundings outside the patient when the insert is removed from the implant . the implant 20 has a supracutaneous portion 25 which defines a seat 26 , and a subcutaneous portion 27 having a side wall 28 and bottom plate 29 defining the cavity 32 in fluid communication with seat 26 . the subcutaneous portion 27 also defines a duct 33 in fluid communication with the cavity 32 . the implant 20 is adapted for implantation in a patient with the duct 33 in fluid communication , e . g ., with the peritoneal cavity , of the patient and the supracutaneous portion 25 exposed outside the patient . the supracutaneous portion 25 remains adjacent the patient &# 39 ; s skin and provides a generally flush appearance which is not only cosmetically desirable , but also reduces the chances of accidental disengagement . the supracutaneous portion may also be made of a skin - like color for cosmetic purposes . the insert 22 is releasably and sealingly mounted on the implant supracutaneous portion 25 . the insert 22 includes a medication accepting means 36 for placing the duct 33 in sealed fluid communication with a medication source . the medication accepting means 36 is a piercable and resealing septum 37 . septum 37 is mounted on a preferably rigid tubular - shaped body member 38 having a side wall 39 that also forms a part of the insert . a medication source such as a syringe and hollow needle can then pierce the septum 37 to deliver a desired medication throught the duct 33 . alternatively , the medication accepting means can include a tube extending from the the body member to allow connection to a pump or similar medication delivery system . the seal means 24 is carried by the implant 20 within the cavity 32 . an engagement surface 41 on the insert 22 coacts with the seal means 24 such that the seal means seals the duct 33 from the ambient surroundings outside the patient when the insert is removed from the implant . the seal means preferably includes a generally cup - shaped closure 42 biased toward and engaging a sealing surface 43 defined by the implant 20 adjacent the seat 26 . the closure 42 preferably has a generally frustoconical side wall 45 about a top plate 46 . the sealing surface 43 has a frustoconical shape matching the closure side wall 45 . the c1osure 42 is shown in fig1 in its first position and in fig2 in its second position . the closure 42 is biased into and maintained in the second position by appropriate biasing means such as spring 51 . any inert material of construction can be used for spring 51 , such as stainless steel or nylon . to assist positioning , alignment means can be provided such as a stud 52 on the closure 42 and a groove 53 on the bottom plate 29 . when the closure 42 is in its second position and sealing the duct 33 and cavity 32 from the ambient surroundings , it is preferred that the top plate 46 is substantially planar with exterior surface 54 of the implant supracutaneous portion 25 . this provides a nonobtrusive surface while protecting the patient from possible contaminants . to prevent relative rotation of the closure 42 with respect to the implant 20 , the implant can be provided with an abutment 48 which cooperates with a notch 49 on the bottom portion of the closure sidewall 45 . as the insert 22 is positioned on the implant 20 , the engagement surface 41 coacts with the closure 42 to move the closure against the urging of spring 51 and into its first position . the duct 33 is then in fluid communication with interior surface 56 of the septum 37 as through a passageway 57 defined by the insert body member 38 . the passageway 57 preferably extends between proximal end 58 and distal end 59 of the body member 38 . the tubular member 38 , passageway 57 , septum 37 , implant 20 and closure 41 preferably have generally circular cross - sections . to enhance sealing between the insert 22 and the implant 20 , the insert can be provided with a flange 61 which extends peripherally about the proximal end 58 of the body member 38 . the flange 61 contacts and seals with the external top surface 54 of the implant supracutaneous portion 25 about the seat 26 . the flange 61 and septum 37 are preferably unitary and molded of a synthetic rubber material such as i010 commercially available from tompkins rubber company , blue bell , pennsylvania . a ridge 62 can also be provided about the septum 37 to provide a target area for the user . the unitary flange 61 and septum 37 combination can be retained on the body member 38 by one or more , usually three , knobs 63 received in sockets 64 defined by the combination . to help retain the insert 22 on the implant 20 , appropriate locking means 67 can be provided . the locking means 67 preferably includes a latch on one of the implant 20 and insert 22 and a detent on the other of the implant and insert . for ease of construction and use , the latch 68 is preferably on the insert 22 and the detent 69 is defined by the side wall 28 of the implant 20 . the latch 68 preferably includes a tab 71 having a distal portion 72 mounted on the body member 38 and a proximal detent engaging portion 73 biased away from the body member wall 39 . the tab 71 can be made of the same material as the body member wall 39 by cutting a generally u - shaped slot 74 in the wall 39 and bending the defined tab outwardly . the biasing of the tab results from a natural resiliency of the material forming the body member wall 39 . the insert body member 38 can be made of any suitable plastic material such as acrylic , polypropylene or polycarbonate . the implant 20 and closure 42 preferably are made of the same materials . as can best be seen in fig3 the detents 69 preferably include a sloping surface 70 which leads to the surface of the wall 28 which , in turn , defines the cavity 32 . thus , as the insert 22 is rotated about one - quarter turn counter - clockwise , as shown in fig3 with respect to the implant 20 , the proximal detent engaging surface 73 travels along the sloped wall 70 until it disengages the detent 69 so that the locking means 67 releases the insert from the implant . this provides for simplified removal and a flat sealing surface 43 . the contact of the flange 61 with the exterior surface 54 inhibits accidental rotation . to assist in embedding the implant 20 in the patient &# 39 ; s body , the implant 20 can be provided with a peripheral collar 76 about the supracutaneous portion 25 adapted to be located just above the skin , and a peripheral flange 77 about the subcutaneous portion adapted to be located just below the skin . the implant flange 77 and collar 76 define between them a circumferential groove 78 into which the epedermis and dermis 12 and surface fat layer 14 are received when the implant is embedded through a patient &# 39 ; s skin . exterior side wall 28 of the subcutaneous portion as well as the surfaces of the flange 77 can be provided with a felt material 80 to facilitate tissue ingrowth . the groove 78 can also be provided with a felt material . in use , e . g ., for peritoneal delivery of medication , the medication introduced into the implant cavity 32 enters the patient through the duct 33 defined by the subcutaneous portion 27 of the implant ( fig1 ). the duct 33 is preferably defined by a hollow boss or stem 81 extending from the sidewall 28 of the subcutaneous portion 27 , and a tube 82 leading from the implant . tube 82 preferably extends through the peritoneum 83 . the far end of the tube 82 can be provided with a disc 84 to safely maintain the tube anchored into the peritoneum . a felt cuff 85 can also be provided adjacent the disc 84 to provide for tissue ingrowth and further anchoring of the far end of the tube 82 . the tube 82 can also lead to another region of the patient &# 39 ; s body , if desired . one particular application for the medical device of the present invention is in the treatment of diabetes . for this purpose , the cavity 32 and duct 33 have a capacity equal to about one day &# 39 ; s supply of insulin . this way , the insulin being delivered to the patient is that which was injected into the device some 24 hours earlier . prepared according to u . s . pharmacopeia formulation , insulin contains antibacterial agents so that any bacteria which somehow may contaminate the insulin or interior of the device will be destroyed within 24 hours . this greatly reduces the danger of peritonitis . a further embodiment to the present invention is a medication delivery system as shown in fig4 and 5 . generally , the medication delivery system includes a connector assembly 88 releasably attached to the medical device 10 . the connector assembly 88 includes the housing 89 which defines a channel 90 in fluid communication with an inlet 91 adapted to be placed in fluid communication with a medication reservoir or pump system ( not shown ) such as by fluid connector 92 . the pump system can be of any medically suitable type such as a peristaltic pump connected to a collapsible medication reservoir . the connector assembly also includes a hollow piercing member such as a needle 93 in fluid communication with the channel 90 and mounted on the housing 89 . the connector assembly 88 also includes attachment means 94 for releasably mounting the connector assembly on the medical device with the needle 93 penetrating the septum and placing the inlet 91 in fluid communication with the duct 33 . the attachment means 94 preferably includes a coupling member 96 having a plurality of legs 97 , usually four , with catches 98 which engage a shoulder 99 about the collar 76 of the implant supracutaneous portion 25 . the legs 97 preferably are spaced about and extend downwardly from a ring 101 . the ring circumscribes but is spaced from a post 102 extending upward from the remainder of the housing 89 . this provides limited relative lateral movement of the coupling assembly 96 with respect to the housing 89 . should the needle 93 not be placed in the exact center of the septum 37 , the ring 101 allows the housing 89 to align with the needle 93 to avoid bending the needle , tearing the septum , or possibly creating a broken channel through the septum which could cause contamination . to maintain the ring 101 about the post 102 , an end plate 103 is provided above the ring on the post 102 . generally the space between the end plate 103 and the housing 89 should be greater than the thickness of the ring to allow a limited amount of tilting of the housing 89 with respect to the insert implant to also assist in aligning the housing with the needle 93 as it is inserted through the septum 37 . the ridge 62 about the septum 37 , together with projections 108 about the needle 93 , provide for a flat resting of the housing 89 on the insert 22 . the post 102 and end plate 103 are preferably part of a cap 104 which is mounted on the main portion 105 of the housing 89 . this provides ease of construction since the needle 93 can be inserted into a bore 106 defined by the housing and having tapered open ends 107 . the cap 104 is thereafter mounted on the housing main portion 105 . after the medical device 10 has been implanted in the patient , the connector assembly 88 can be mounted on the medical device as shown in fig4 and 5 and connected to a medication reservoir and pump system . medication can then be given to the patient continously or intermittently without patient intervention . provision can also be made to have a sensor located on the exterior surface of the implant and having leads which are accessible on the supracutaneous portion of the implant . those leads can then be connected to a microcomputer of an infusion device or to an appropriate monitoring system such as a meter or alarm device .
an implantable medical device and system for percutaneous administration of a medication from an external source is disclosed . continuous , variable rate , or intermittent administration of medication can be effected without the need for repeated puncturing of the patient &# 39 ; s skin . the present device includes an implant that is transcutaneously anchored to the patient , an insert releasably mounted on the implant , and a seal means on the implant which seals an implant cavity that receives the insert upon removal of the insert so that the patient is protected from infection while the insert is replaced .